What is a stock summary page? Click here for an overview.
Business Description
Nephros Inc
NAICS : 339112
SIC : 3841
ISIN : US6406714005
Description
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.67 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | 6.22 | |||||
| Interest Coverage | 6 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -13.47 | |||||
| Beneish M-Score | -1.69 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 13.3 | |||||
| 3-Year EBITDA Growth Rate | 34.4 | |||||
| 3-Year EPS without NRI Growth Rate | 35 | |||||
| 3-Year Book Growth Rate | -14.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.93 | |||||
| 9-Day RSI | 41.64 | |||||
| 14-Day RSI | 43.86 | |||||
| 3-1 Month Momentum % | -2.78 | |||||
| 6-1 Month Momentum % | -11.95 | |||||
| 12-1 Month Momentum % | -29.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.31 | |||||
| Quick Ratio | 3.64 | |||||
| Cash Ratio | 2.41 | |||||
| Days Inventory | 184.76 | |||||
| Days Sales Outstanding | 43.11 | |||||
| Days Payable | 56.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.2 | |||||
| Shareholder Yield % | -4.67 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 61.59 | |||||
| Operating Margin % | 0.04 | |||||
| Net Margin % | 0.52 | |||||
| FCF Margin % | -14.18 | |||||
| ROE % | 0.9 | |||||
| ROA % | 0.66 | |||||
| ROIC % | 0.08 | |||||
| 3-Year ROIIC % | -80.64 | |||||
| ROC (Joel Greenblatt) % | 1.81 | |||||
| ROCE % | 0.95 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | N/A |
N/A
|
N/A
| |||
| Forward PE Ratio | 71.58 | |||||
| PE Ratio without NRI | N/A |
N/A
|
N/A
| |||
| PS Ratio | 1.13 | |||||
| PB Ratio | 1.85 | |||||
| Price-to-Tangible-Book | 2.23 | |||||
| EV-to-EBIT | 156.27 | |||||
| EV-to-EBITDA | 61.96 | |||||
| EV-to-Revenue | 0.99 | |||||
| EV-to-FCF | -6.62 | |||||
| Price-to-GF-Value | 0.74 | |||||
| Price-to-Median-PS-Value | 0.2 | |||||
| Price-to-Graham-Number | 11.33 | |||||
| Price-to-Net-Current-Asset-Value | 2.89 | |||||
| Price-to-Net-Cash | 13.6 | |||||
| Earnings Yield (Greenblatt) % | 0.64 | |||||
| FCF Yield % | -12.37 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nephros Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 13.127 | ||
| EPS (TTM) (€) | 0.001 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 39.08 | ||
| 14-Day RSI | 43.86 | ||
| 14-Day ATR (€) | 0.041129 | ||
| 20-Day SMA (€) | 1.408 | ||
| 12-1 Month Momentum % | -29.65 | ||
| 52-Week Range (€) | 1.24 - 2.16 | ||
| Shares Outstanding (Mil) | 10.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nephros Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nephros Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nephros Inc Frequently Asked Questions
What is Nephros Inc(FRA:NPJP)'s stock price today?
The current price of FRA:NPJP is €1.36. The 52 week high of FRA:NPJP is €2.16 and 52 week low is €1.24.
When is next earnings date of Nephros Inc(FRA:NPJP)?
The next earnings date of Nephros Inc(FRA:NPJP) is 2025-05-09 Est..
Does Nephros Inc(FRA:NPJP) pay dividends? If so, how much?
Nephros Inc(FRA:NPJP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers